2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.
Shanu Modi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial (NCT03734029) in patients with HER2-low metastatic breast cancer.
The DESTINY-Breast04 trial evaluates fam-trastuzumab deruxtecan-nxki (Enhertu) in comparison with a physician’s choice of chemotherapy in patients with HER2-low, hormone receptor (HR)–positive metastatic breast cancer.
The primary end point of progression free survival (PFS) improved outcomes for this patient population with a hazard ratio of approximately 0.5, allowing investigators to test all patients enrolled on the study, Modi explains. Similarly, trastuzumab deruxtecan elicited a was statistically significant benefit in median PFS among all treated patients increasing the median from approximately 5 months to approximately 10 months, Modi adds.
One of the key secondary end points was overall survival, resulting in similar results for the hormone receptor–positive group, as well as the overall total patients on study, Modi continues. This led to an improvement in median OS from approximately 17 months to almost 24 months with trastuzumab deruxtecan, Modi says. These data are compelling efficacy data to see for patients with advanced breast cancer, Modi concludes.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®.